malaria vaccine

The ligands that pathogens use to invade their target cells have often proven to be good targets for vaccine development.

No abstract available

The RTS,S/AS02D malaria vaccine administered to young infants has a good safety profile and remains efficacious over 14 months.

The concept of a malaria vaccine has sparked great interest for decades; however, the challenge is proving to be a difficult one.

Immunization with PfCelTOS resulted in potent humoral and cellular immune responses and most importantly induced sterile protection against a heterologous challenge with P. berghei sporozoites in a proportion of both inbred and outbred mice.

The immunological mechanisms responsible for protection against malaria infection vary among Plasmodium species, host species and the developmental stage of parasite, and are poorly understood. A challenge with live parasites is the most relevant approach to testing the efficacy of experimental malaria vaccines.

This study provided valuable information on epitopes of PfCP-2.9 vaccine candidate through generation of a panel of mAbs and a series of PfCP-2.9 mutants. The information may prove to be useful for designing more effective malaria vaccines against blood-stage parasites.

Longitudinal cohort studies are important to describe the dynamics of naturally acquired antibody response profiles to defined Plasmodium falciparum malaria antigens relative to clinical malaria episodes.

Currently these spreadsheets represent the most complete publicly available summary of malaria vaccine projects at advanced pre-clinical and clinical stages globally.